Aditxt, Inc. - ADTX STOCK NEWS

Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.

Aditxt, Inc. (NASDAQ: ADTX) is an innovative life sciences company specializing in the development and commercialization of immune monitoring and modulation technologies. The company's mission is to advance humanity into the 'age of immunity' by decoding and harnessing the immune system for better health outcomes.

Aditxt's portfolio includes two flagship programs: Adimune™ and AditxtScore™. Adimune™ is focused on creating immunotherapies that promote tolerance to transplanted organs, while AditxtScore™ offers advanced immune monitoring solutions. The company's products and technologies aim to address critical medical needs, such as preventing organ transplant rejection, managing autoimmune diseases, and providing personalized diagnostic insights.

Recently, Aditxt has expanded its reach by acquiring strategic assets and forming new partnerships. Notably, its subsidiary Pearsanta, Inc. acquired MDNA Life Sciences’ proprietary early disease and cancer detection platform, including Mitomic™ technology. This acquisition enhances Aditxt's capabilities in precision diagnostics and early disease detection, with applications spanning various cancers and other serious health conditions.

Financially, Aditxt has shown robust growth through strategic acquisitions and innovative product development. The company’s commitment to enhancing patient outcomes through cutting-edge technologies is evident in its expanding product line and growing market presence.

For more information, visit the official website at aditxt.com.

12/12/2023 08:30 AM

News

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally

Rhea-AI Summary

Evofem Biosciences, Inc. (EVFM) and Aditxt, Inc. (ADTX) have announced a definitive agreement for Aditxt to acquire Evofem in a transaction valued at approximately $100 million. Evofem, the creator of the FDA-approved hormone-free contraceptive gel, Phexxi®, has posted $13.4 million in net sales for the first nine months of 2023. Aditxt aims to accelerate Evofem into the global non-hormonal birth control market, projected to grow from $27.7 billion in 2022 to $52.2 billion by 2031.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

60.26%

Tags

10/06/2023 08:00 AM

News

Aditxt, Inc. to Present at 8th Annual Dawson James Conference

Rhea-AI Summary

Aditxt CEO to present at 8th Annual Dawson James Conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.14%

Tags

10/05/2023 08:00 AM

News

Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform

Rhea-AI Summary

Aditxt appoints Ernie Lee as CEO of Pearsanta to accelerate the commercial launch of Test2Treat.me, a clinical diagnostic testing services platform for healthcare providers and consumers.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.36%

Tags

09/08/2023 07:05 AM

News

Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023

Rhea-AI Summary

Aditxt CEO to deliver company presentation at H.C. Wainwright Global Investment Conference on September 13th

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.16%

Tags

09/06/2023 04:30 PM

News

Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Rhea-AI Summary

Aditxt, Inc. closes private placement, raising $10.0 million for working capital and general corporate purposes.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.68%

Tags

08/31/2023 07:00 PM

News

Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Rhea-AI Summary

Aditxt announces private placement offering of 1,000,000 shares of common stock at $10.00 per share, expected to raise $10.0 million

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-24.8%

Tags

08/18/2023 07:02 AM

News

Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

Rhea-AI Summary

Aditxt provides update on innovation programs and strategic M&A initiatives.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.62%

Tags

08/17/2023 12:00 PM

News

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023

Rhea-AI Summary

Aditxt announces 1-for-40 reverse stock split to comply with Nasdaq's minimum bid price requirement.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

31.58%

Tags

08/17/2023 12:00 PM

News

CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023

Rhea-AI Summary

Aditxt, Inc. (NASDAQ: ADTX) announces a 1-for-40 reverse stock split effective on August 18, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

31.58%

Tags

06/20/2023 07:49 AM

News

Aditxt, Inc.’s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics

Rhea-AI Summary

Aditxt, a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed a non-binding Letter of Intent to acquire Natural State Laboratories and Natural State Genomics. The acquisition would support revenue growth and provide Pearsanta with an expanded management team. The consideration for the transaction is not to exceed $55 million.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.08%

Tags

FAQ

What is the current stock price of Aditxt (ADTX)?

The current stock price of Aditxt (ADTX) is $0.187 as of December 23, 2024.

What is the market cap of Aditxt (ADTX)?

The market cap of Aditxt (ADTX) is approximately 3.0M.

What is Aditxt, Inc.'s core business?

Aditxt, Inc. specializes in developing and commercializing technologies for monitoring and modulating the human immune system. Its key focus areas include preventing organ transplant rejection and managing autoimmune diseases.

What are the main products offered by Aditxt?

Aditxt's main products include Adimune™, which focuses on immune tolerance for organ transplants, and AditxtScore™, a platform for advanced immune monitoring.

What recent acquisitions has Aditxt made to enhance its capabilities?

Aditxt's subsidiary Pearsanta, Inc. recently acquired MDNA Life Sciences' early disease and cancer detection platform, including Mitomic™ technology. This acquisition expands Aditxt's capabilities in precision diagnostics.

What is the significance of Aditxt's Adimune™ program?

The Adimune™ program aims to create immunotherapies that promote tolerance to transplanted organs, helping to prevent organ rejection and manage autoimmune conditions.

How does AditxtScore™ contribute to the company's mission?

AditxtScore™ offers advanced immune monitoring solutions that provide personalized diagnostic insights, aiding in the management of immune-related diseases and improving patient outcomes.

What is Mitomic™ technology, and how does it benefit Aditxt?

Mitomic™ technology, acquired by Pearsanta, Inc., is an early disease and cancer detection platform that uses mitochondrial DNA to detect diseases at their earliest stages. This technology enhances Aditxt's precision diagnostics capabilities.

What financial achievements has Aditxt made recently?

Aditxt has shown strong financial growth through strategic acquisitions and product development. The company's expansion into new markets and innovative technologies underscores its commitment to improving patient outcomes.

Who are Aditxt's target customers?

Aditxt targets healthcare providers, researchers, and patients in need of advanced immunotherapy and diagnostic solutions, particularly those dealing with organ transplants, autoimmune diseases, and early disease detection.

How does Aditxt's strategic acquisition align with its mission?

Aditxt's strategic acquisitions, such as the MDNA Life Sciences' platform, align with its mission by enhancing its capabilities in precision diagnostics and early disease detection, which are critical for advancing public health.